Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.57 |
| ▸ | MMP1 | P03956 | 4/20 | 0.57 |
| ▸ | MMP9 | P14780 | 4/20 | 0.57 |
| ▸ | MMP13 | P45452 | 4/20 | 0.57 |
| ▸ | MMP3 | P08254 | 3/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 3/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884127 | 1.00 | MMP2 (0.57) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL5734780 | 0.86 | TSHR (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3951678 | 0.86 | ADAMTS4 (0.69) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL5734792 | 0.86 | TSHR (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL13890464 | 0.86 | MMP2 (0.57) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL4380323 | 0.86 | ADAMTS4 (0.69) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL28502922 | 0.86 | TSHR (0.56) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL3951681 | 0.86 | ADAMTS4 (0.69) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL6325782 | 0.84 | ADAMTS4 (0.61) | MMP2MMP1MMP9MMP13MMP3 | |
| SCHEMBL2337573 | 0.83 | ALDH1A1 (0.56) | MMP2MMP1MMP9MMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| EP-2013184-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007129019-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1378507-B1 | Process for producing optically active imidazole derivatives, intermediates and synthesis thereof | MITSUBISHI PHARMA CORP (JP) | 2006-08-23 | — | — | EP | disclosed |
| EP-1378507-A2 | Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same | Mitsubishi Pharma Corporation (JP) | 2004-01-07 | — | — | EP | disclosed |
| CN-1133623-C | Process for producing optically active imidazole compound, intermediate for synthesis thereof, and process for producing the same | ������ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-6166221-A | Production method of optically active imidazole compound, synthetic intermediate therefor and production method thereof | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6066739-A | Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-05-23 | — | — | US | disclosed |
| CN-1251093-A | Process for producing optically active imidazole compound, intermediates for synthesizing same | YOSHITOMI PHARMACEUTICAL (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0972768-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE IMIDAZOLE COMPOUNDS, INTERMEDIATES FOR SYNTHESIZING THE SAME, AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111860-A1 | SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS | ADGRE5, ADGRF1, SELPLG | MMP2 3625/4885MMP1 2733/4885MMP9 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.